期刊文献+

原钙黏蛋白-20在肺癌组织中表达及其机制 被引量:2

Expression and potential mechanism of protocadherins 10 in lung cancer tissues
原文传递
导出
摘要 目的 探讨原钙黏蛋白-20 (PCDH20)的表达与其启动子区甲基化水平的关系以及PCDH20基因在肺癌发生、发展中的作用及相关的作用机制.方法 采用半定量逆转录-聚合酶链反应(SqRT-PCR)检测PCDH20在15例正常成人肺组织和20例肺癌组织的表达;用甲基化特异性PCR(MSP)检测20例肺癌组织中PCDH20启动子区的甲基化水平.结果 PCDH20在几乎所有正常组织中表达,在95%的肺癌组织中不表达(19/20).80%的肺癌组织中存在PCDH20启动子的甲基化,而在正常肺组织中未检测到.结论 DNA甲基化是PCDH20在肺癌中表达下调或缺失的原因之一,PCDH20在大肠癌的发生发展中起抑制作用. Objective To explore the function and potential mechanism of protocadherin 20 (PCDH20) gene in lung cancer development.Methods Expression of PCDH20 was detected in 15 cases of normal adult tissues and 20 cases of lung cancer by semi-quantitative reverse transcription-polymerase chain reaction (SqRT-PCR),and the level of PCDH20 promoter methylation in lung cancer and normal tissues was evaluated by methylation-specific PCR (MSP).Results PCDH20 was expressed in all normal adult tissues but low or silenced in 95% (19/20) lung cancer tissue.Methylation of the CpG-rich promoter region of PCDH20 was detected in 80% (12/15) lung tumors,which was significantly different from the status in normal lung tissues (P < 0.01).Conclusion These results suggest that epigenetic silencing of PCDH20 is common in lung cancer,and PCDH20 acts as a tumor suppressor in the carcinogenesis.
作者 卓毅 冯茂辉
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2014年第9期2044-2045,共2页 Chinese Journal of Experimental Surgery
关键词 肺癌 原钙黏蛋白-20 Lung cancer Protocadherins 20
  • 相关文献

参考文献7

  • 1Yagi T.Clustered protocadherin family[J].Dev Growth Differ,2008,50 Suppl 1:S131-S140.
  • 2Hirayama T,Hasegawa S,Yagi T.Clustered protocadherin family[J].Tanpakushitsu Kakusan Koso,2008,53 (4 Suppl):358-364.
  • 3Kim SY,Chung HS,Sun W,et al.Spatiotemporal expression pattern of non-clustered protocadherin family members in the developing rat brain[J].Neuroscience,2007,147 (4):996-1021.
  • 4Terry S,Queires L,Gil-Diez-de-Medina S,et al.Protocadherin-PC promotes androgen-independent prostate cancer cell growth[J].Prostate,2006,66(10):1100-1113.
  • 5Terry S,Maille P,Baaddi H,et al.Cross modulation between the androgen receptor axis and protocadherin-PC in mediating neuroendocrine transdifferentiation and therapeutic resistance of prostate cancer[J].Neoplasia,2013,15 (7):761-772.
  • 6Yang X,Chen MW,Terry S,et al.A human-and male-specific protocadherin that acts through the wnt signaling pathway to induce neuroendocrine transdifferentiation of prostate cancer cells[J].Cancer Res,2005,65(12):5263-5271.
  • 7Ke C,Li C,Huang X,et al.Protocadherin20 promotes excitatory synaptogenesis in dorsal horn and contributes to bone cancer pain[J].Neuropharmaeology,2013,75:181-190.

同被引文献18

  • 1盛旺,吕晓君,安汉祥.肺癌组织中水通道蛋白的表达及其与上皮-间质转化的相关性[J].中国老年学杂志,2015,35(2):362-363. 被引量:4
  • 2MOORE L E, PFEIFFER R M, ZHANG Z, et al. Pro- teomic biomarkers in combination with CA 125 for detec- tion of epithelial ovarian cancer using prediagnostic ser- um samples from the Prostate, Lung, Colorectal, and O- varian (PLCO) Cancer Screening Trial [ J ]. Cancer,2012, 118(1) :91-100.
  • 3KARIMI S, MOHAMADNIA A, NADJI S A,et al. Expres- sion of two basic mrna biomarkers in peripheral blood of patients with non-small cell lung cancer detected by real- time RT-PCR, individually and simultaneously [ J ]. Iran Biomed J,2015,19 ( 1 ) : 17-22.
  • 4CHEN X, HU Z, WANG W, et al. Identification of ten ser- um microRNAs from a genome-wide serum microRNA ex- pression profile as novel noninvasive biomarkers for nons- mall cell lung cancer diagnosis [ J]. Int J Cancer, 2012, 130(7) :1620-1628.
  • 5OKAMURA K, TAKAYAMA K, IZUMI M, et al. Diagnos- tic value of CEA and CYFRA 21-1 tumor markers in pri- mary lung cancer[ J]. Lung Cancer,2013,80( 1 ) :45-49.
  • 6LEE D S,KIM Y S,JUNG S L,et al. The relevance of ser- um carcinoembryonic antigen as an indicator of brain me- tastasis detection in advanced non-small cell lung cancer [ J]. Tumor Bio1,2012,33 (4) : 1065-1073.
  • 7VON PAWEL J, HARVEY J H, SPIGEL D R, et al. Phase II trial of mapatumumab, a fully human agonist mono- clonal antibody to tumor necrosis factor-related apoptosis- inducing ligand receptor l ( TRAIL-R1 ), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer[ J]. Clin Lung Cancer,2014, 15(3) :188-196. e2.
  • 8PARK B J, CHA M K, KIM I H. Thioredoxin 1 as a serum marker for breast cancer and its use in combination with CEA or CA15-3 for improving the sensitivity of breast cancer diagnoses [J]. BMC Res Notes,2014,7 ( 1 ) :7.
  • 9RUDIN C M, HANN C L, GARON E B, et al. Phase II study of single-agent navitoclax( ABT-263 ) and biomarker correlates in patients with relapsed small cell lung cancer [J]. Clin Cancer Res,2012,18 (11) :3163-3169.
  • 10张军,祁娟,郭义.HDGF和ADAM9在非小细胞肺癌中的异常表达及其临床意义[J].中国医科大学学报,2011,40(3):280-281. 被引量:6

引证文献2

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部